# Howard Gurney

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/howard-gurney/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,686 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 64 |
| i10-index | 205 |
| Last Known Institution | Macquarie University |
| OpenAlex ID | https://openalex.org/A5041526616 |
| ORCID iD | https://orcid.org/0000-0003-0217-5261 |
| Works | 453 |

## Researcher papers

- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://scholariq.org/papers/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma/)
- [Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma](https://scholariq.org/papers/avelumab-maintenance-therapy-for-advanced-or-metastatic-urothelial-carcinoma/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)

## Researcher university

- [Macquarie University](https://scholariq.org/institutions/macquarie-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.